:: CLDF ::

1.	Albumin: Indications in chronic liver disease
	Tufoni M¹, Zaccherini G¹, Caraceni P¹, Bernardi M¹. United European Gastroenterol J. 2020 Feb 26:2050640620910339. doi: 10.1177/2050640620910339. [Epub ahead of print]

2.	Complications Associated with Anesthesia Services in Endoscopic Procedures Among Patients with Cirrhosis
	Lieber SR¹, Heller BJ², Howard CW², Sandler RS¹, Crockett S¹, Barritt AS¹. Hepatology. 2020 Mar 10. doi: 10.1002/hep.31224.

3.	Inpatient Mortality Benefit with Transjugular Intrahepatic Portosystemic Shunt for Hospitalized Hepatorenal Syndrome Patients
	Charilaou P¹, Devani K², Petrosyan R³, Reddy C², Pyrsopoulos N⁴. Dig Dis Sci. 2020 Feb 15. doi: 10.1007/s10620-020-06136-2. [Epub ahead of print]

4.	Continuous terlipressin infusion is associated with improved diet intake and muscle strength in patients awaiting liver transplant
	Chapman B¹, Gow P², Sinclair M², Hanrahan T², Angus P², McClure T², Mills C², Terbah R², Testro A². JHEP Rep. 2019 May 17;1(2):107-113. doi: 10.1016/j.jhepr.2019.05.002. eCollection 2019 Aug.

5.	Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes
	Vizzutti F¹, Schepis F², Arena U¹, Fanelli F³, Gitto S¹, Aspite S¹, Turco L², Dragoni G¹, Laffi G¹, Marra F^4,5. Intern Emerg Med. 2020 Jan 9. doi: 10.1007/s11739-019-02252-8. [Epub ahead of print]

6.	Diagnosis and management of renal dysfunction in patients with cirrhosis
	Carrion AF¹, Radhakrishnan R², Martin P¹. Expert Rev Gastroenterol Hepatol. 2019 Dec 30:1-7. doi: 10.1080/17474124.2020.1708190. [Epub ahead of print]

7.	Peptide-based therapy in portal hypertension
	Mohanty A¹. Curr Opin Endocrinol Diabetes Obes. 2019 Dec 6. doi: 10.1097/MED.0000000000000528. [Epub ahead of print]

8.	Hepatorenal Syndrome Type 1: Current Challenges And Future Prospects
	Facciorusso A¹. Ther Clin Risk Manag. 2019 Nov 27;15:1383-1391. doi: 10.2147/TCRM.S205328. eCollection 2019.

9.	Impaired Cardiac Reserve on Dobutamine Stress Echocardiography Predicts the Development of Hepatorenal Syndrome
	Koshy AN^1,2, Farouque O^1,2, Cailes B¹, Testro A³, Ramchand J^1,2, Sajeev JK¹, Han HC^1,2, Srivastava PM¹, Jones EF¹, Salehi H¹, Teh AW^1,2, Lim HS^1,2, Calafiore P¹, Gow PJ^2,3. Am J Gastroenterol. 2019 Nov 15. doi: 10.14309/ajg.0000000000000462. [Epub ahead of print]

10.	Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis
	Velez JCQ^1,2, Therapondos G³, Juncos LA^4,5. Nat Rev Nephrol. 2019 Nov 13. doi: 10.1038/s41581-019-0218-4. [Epub ahead of print]

11.	Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension: Review and Update of the Literature
	Hung ML¹, Lee EW². Clin Liver Dis. 2019 Nov;23(4):737-754. doi: 10.1016/j.cld.2019.07.004. Epub 2019 Aug 31.

12.	Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis
	Thomson MJ^1,2, Taylor A³, Sharma P⁴, Lok AS^4,5, Tapper EB^4,5,6. Dig Dis Sci. 2019 Sep 30. doi: 10.1007/s10620-019-05858-2. [Epub ahead of print]

13.	Ascites and Hepatorenal Syndrome
	Adebayo D¹, Neong SF¹, Wong F². Clin Liver Dis. 2019 Nov;23(4):659-682. doi: 10.1016/j.cld.2019.06.002. Epub 2019 Aug 7.

14.	Gender Disparity in Inpatient Mortality After Transjugular Intrahepatic Portosystemic Shunt Creation in Patients Admitted With Hepatorenal Syndrome: A Nationwide Study
	Trivedi PS¹, Brown MA², Rochon PJ², Ryu RK², Johnson DT³. J Am Coll Radiol. 2019 Sep 18. pii: S1546-1440(19)31021-X. doi: 10.1016/j.jacr.2019.08.020. [Epub ahead of print]

15.	Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis
	Best LM¹, Freeman SC, Sutton AJ, Cooper NJ, Tng EL, Csenar M, Hawkins N, Pavlov CS, Davidson BR, Thorburn D, Cowlin M, Milne EJ, Tsochatzis E, Gurusamy KS. Cochrane Database Syst Rev. 2019 Sep 12;9:CD013103. doi: 10.1002/14651858.CD013103.pub2. [Epub ahead of print]

16.	Evolution of diagnostic criteria for acute kidney injury in patients with decompensated cirrhosis: A prospective study in a tertiary university hospital
	Vaz NF¹, da Cunha VNR¹, Cunha-Silva M¹, Sevá-Pereira T¹, de Souza Almeida JR¹, Mazo DF². Clin Res Hepatol Gastroenterol. 2019 Aug 16. pii: S2210-7401(19)30169-X. doi: 10.1016/j.clinre.2019.07.004. [Epub ahead of print]

17.	A clinical risk prediction model to identify patients with hepatorenal syndrome at hospital admission
	Koola JD^1,2,3, Chen G⁴, Malin BA^5,6,7, Fabbri D^5,7, Siew ED^1,8, Ho SB^9,10, Patterson OV^11,12, Matheny ME^1,5,6,13. Int J Clin Pract. 2019 Jul 26:e13393. doi: 10.1111/ijcp.13393. [Epub ahead of print]

18.	Point-of-Care Echocardiography Unveils Misclassification of Acute Kidney Injury as Hepatorenal Syndrome
	Velez JCQ^1,2, Petkovich B³, Karakala N⁴, Huggins JT³. Am J Nephrol. 2019 Aug 8:1-8. doi: 10.1159/000501299. [Epub ahead of print]

19.	Vascular syndromes in liver cirrhosis
	Shenoda B¹, Boselli J^2,3. Clin J Gastroenterol. 2019 Apr 12. doi: 10.1007/s12328-019-00956-0. [Epub ahead of print]

20.	News in Pathophysiology, Definition and Classification of Hepatorenal Syndrome: a step beyond the International Club of Ascites (ICA) Consensus document
	Angeli P¹, Garcia-Tsao G², Nadim MK³, Parikh CR⁴. J Hepatol. 2019 Jul 11. pii: S0168-8278(19)30410-6. doi: 10.1016/j.jhep.2019.07.002. [Epub ahead of print]

21.	Albumin in Cirrhosis: More Than a Colloid
	Paine CH¹, Biggins SW^2,3, Pichler RH⁴. Curr Treat Options Gastroenterol. 2019 Jun;17(2):231-243. doi: 10.1007/s11938-019-00227-4.

22.	Role of endotoxemia in causing renal dysfunction in cirrhosis
	Peng JL^#1, Techasatian W^#1, Hato T², Liangpunsakul S^1,3. J Investig Med. 2019 Jul 19. pii: jim-2019-001056. doi: 10.1136/jim-2019-001056. [Epub ahead of print]

23.	Predictors, burden and impact of cardiac arrhythmias among patients hospitalized with end-stage liver disease
	Adejumo AC¹, Adejumo KL², Akanbi O³, Adegbala OM⁴, Alayo QA⁵, Fijabi DO⁶, Ogundipe OA⁷, Almaddah N⁸, Pani L⁹, Adeboye A¹⁰. Heart Lung. 2019 Jul 15. pii: S0147-9563(19)30103-7. doi: 10.1016/j.hrtlng.2019.07.002. [Epub ahead of print]

24.	Critically Ill Patients with End-Stage Liver Disease
	Crager S¹. Emerg Med Clin North Am. 2019 Aug;37(3):511-527. doi: 10.1016/j.emc.2019.03.008. Epub 2019 May 21.

25.	Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data
	Kazory A¹, Ronco C^2,3. Cardiorenal Med. 2019;9(1):1-7. doi: 10.1159/000492791. Epub 2018 Sep 17.

26.	Management and outcomes of hepatorenal syndrome at an urban academic medical center: a retrospective study
	Bashir MH¹, Iqbal S, Miller R, Singh J, Mubarak G, Likhtshteyn M, Bigajer E, Gallagher B, Hurairah A, Stefanov D, McFarlane SI, Ferstenberg R. Eur J Gastroenterol Hepatol. 2019 Jun 4. doi: 10.1097/MEG.0000000000001462. [Epub ahead of print]

27.	Terlipressin Phase 3 CONFIRM Trial in HRS-1 Achieves Full Enrollment

28.	Hepatorenal Syndrome
	Francoz C^1,2, Durand F^1,2, Kahn JA³, Genyk YS⁴, Nadim MK⁵. Clin J Am Soc Nephrol. 2019 May 7;14(5):774-781. doi: 10.2215/CJN.12451018. Epub 2019 Apr 17.

29.	Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data
	Kazory A¹, Ronco C^2,3. Cardiorenal Med. 2019;9(1):1-7. doi: 10.1159/000492791. Epub 2018 Sep 17.

30.	Effect of Renal Diagnosis on Survival in Simultaneous Liver-Kidney Transplantation
	Cannon RM¹, Jones CM², Davis EG², Eckhoff DE³. J Am Coll Surg. 2019 Apr;228(4):536-544.e3. doi: 10.1016/j.jamcollsurg.2018.12.003. Epub 2018 Dec 23.

31.	Outcomes of renal dysfunction in patients with acute liver failure
	Hadem J^1,2, Kielstein JT^3,4, Manns MP¹, Kümpers P⁵, Lukasz A⁵. United European Gastroenterol J. 2019 Apr;7(3):388-396. doi: 10.1177/2050640618817061. Epub 2018 Dec 3.

32.	Acute kidney injury in cirrhosis: implications for liver transplantation
	MacDonald AJ¹, Nadim MK², Durand F^3,4, Karvellas CJ^5,6. Curr Opin Crit Care. 2019 Apr;25(2):171-178. doi: 10.1097/MCC.0000000000000590.

33.	Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome
	Amin AA¹, Alabsawy EI², Jalan R³, Davenport A⁴. Semin Nephrol. 2019 Jan;39(1):17-30. doi: 10.1016/j.semnephrol.2018.10.002.

34.	The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records
	Jamil K¹, Huang X¹, Lovelace B², Pham AT^2,3, Lodaya K⁴, Wan G¹. J Med Econ. 2019 May;22(5):421-429. doi: 10.1080/13696998.2019.1580201. Epub 2019 Mar 4.

35.	The emergency medicine evaluation and management of the patient with cirrhosis
	Long B¹, Koyfman A². Am J Emerg Med. 2018 Apr;36(4):689-698. doi: 10.1016/j.ajem.2017.12.047. Epub 2017 Dec 23.

36.	Hepatorenal syndrome
	Ginès P^1,2,3, Solà E^4,5,6, Angeli P⁷, Wong F⁸, Nadim MK⁹, Kamath PS¹⁰. Nat Rev Dis Primers. 2018 Sep 13;4(1):23. doi: 10.1038/s41572-018-0022-7.

37.	Hepatorenal syndrome: the clinical impact of vasoactive therapy
	Colle I¹, Laterre PF². Expert Rev Gastroenterol Hepatol. 2018 Feb;12(2):173-188. doi: 10.1080/17474124.2018.1417034. Epub 2017 Dec 19.

38.	Well Preserved Renal Function in Children With Untreated Chronic Liver Disease
	Berg UB¹, Németh A. J Pediatr Gastroenterol Nutr. 2018 Apr;66(4):575-580. doi: 10.1097/MPG.0000000000001862.

39.	Biology of portal hypertension
	McConnell M¹, Iwakiri Y². Hepatol Int. 2018 Feb;12(Suppl 1):11-23. doi: 10.1007/s12072-017-9826-x. Epub 2017 Oct 26.

40.	Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis
	Patidar KR¹, Kang L², Bajaj JS¹, Carl D³, Sanyal AJ¹. Hepatology. 2018 Jul;68(1):224-233. doi: 10.1002/hep.29772. Epub 2018 May 17.

41.	Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
	Allegretti AS¹, Israelsen M, Krag A, Jovani M, Goldin AH, Schulman AR, Winter RW, Gluud LL. Cochrane Database Syst Rev. 2017 Jun 14;6:CD005162. doi: 10.1002/14651858.CD005162.pub4.

42.	Renal Function in Cirrhosis: A Critical Review of Available Tools
	Piano S¹, Brocca A¹, Angeli P¹. Semin Liver Dis. 2018 Aug;38(3):230-241. doi: 10.1055/s-0038-1661372. Epub 2018 Jul 24.

43.	Hepatorenal Syndrome: Physiology, Diagnosis and Management
	Chmielewski J¹, Lewandowski RJ^2,3,4, Maddur H⁵. Semin Intervent Radiol. 2018 Aug;35(3):194-197. doi: 10.1055/s-0038-1660797. Epub 2018 Aug 6.

44.	Renal Failure in Patients with Liver Cirrhosis: Novel Classifications, Biomarkers, Treatment
	Appenrodt B¹, Lammert F¹. Visc Med. 2018 Aug;34(4):246-252. doi: 10.1159/000492587. Epub 2018 Aug 14.

45.	Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis
	Kalambokis GN¹, Tsiakas I¹, Christaki M¹, Koustousi C¹, Christou L¹, Baltayiannis G², Christodoulou D². Eur J Gastroenterol Hepatol. 2018 Jun;30(6):659-667. doi: 10.1097/MEG.0000000000001088.

46.	Development of an automated phenotyping algorithm for hepatorenal syndrome
	Koola JD¹, Davis SE², Al-Nimri O³, Parr SK⁴, Fabbri D⁵, Malin BA⁶, Ho SB⁷, Matheny ME⁸. J Biomed Inform. 2018 Apr;80:87-95. doi: 10.1016/j.jbi.2018.03.001. Epub 2018 Mar 9.

47.	Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial
	Stine JG¹, Wang J², Cornella SL¹, Behm BW¹, Henry Z¹, Shah NL¹, Caldwell SH¹, Northup PG¹. Ann Hepatol. 2018 Mar 1;17(2):300-306. doi: 10.5604/01.3001.0010.8660.

48.	Chronic kidney disease in patients with chronic hepatitis C virus infection
	Shahab O¹, Golabi P², Younossi ZM^3,2. Minerva Gastroenterol Dietol. 2018 Dec;64(4):376-382. doi: 10.23736/S1121-421X.18.02466-2. Epub 2018 Jan 10.

49.

Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome

Piano S¹, Schmidt HH², Ariza X³, Amoros A⁴, Romano A¹, Hüsing-Kabar A², Solà E³, Gerbes A⁵, Bernardi M⁶, Alessandria C⁷, Scheiner B⁸, Tonon M¹, Maschmeier M², Solè C³, Trebicka J⁹, Gustot T¹⁰, Nevens F¹¹, Arroyo V⁴, Gines P¹², Angeli P¹³; EASL CLIF Consortium, European Foundation for the Study of Chronic Liver Failure (EF Clif). Clin Gastroenterol Hepatol. 2018 Nov;16(11):1792-1800.e3. doi: 10.1016/j.cgh.2018.01.035. Epub 2018 Jan 31.

New Treatment Advances & Current Management Approaches in Acute Kidney Injury - Hepatorenal Syndrome(AKI-HRS)